Achieve Life Sciences (ACHV) to Release Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHV) is expected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.06). On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Achieve Life Sciences Price Performance

Shares of Achieve Life Sciences stock opened at $2.97 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.78 and a quick ratio of 6.78. The firm has a fifty day moving average price of $3.08 and a two-hundred day moving average price of $3.94. Achieve Life Sciences has a fifty-two week low of $2.51 and a fifty-two week high of $5.59. The company has a market cap of $103.01 million, a PE ratio of -2.63 and a beta of 1.67.

Insider Buying and Selling at Achieve Life Sciences

In other Achieve Life Sciences news, CFO Mark K. Oki bought 10,000 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were acquired at an average cost of $2.89 per share, for a total transaction of $28,900.00. Following the transaction, the chief financial officer now owns 10,000 shares in the company, valued at approximately $28,900. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 2.00% of the company’s stock.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.